airPharma
This article was originally published in Start Up
Executive Summary
When it came time to build a pipeline, airPharma's founders turned to a product they knew well for their lead compound:a drug formerly marketed as Pumactant, for neonatal respiratory distress. This compound is an inhalable synthetic pulmonary surfactant. The symptoms of asthma have been associated with surfactant dysfunction.
You may also be interested in...
The Asthma Challenge: Not Solved Yet
Asthma represents one of the blockbuster markets in the pharmaceutical industry; sales of drugs from 10 companies amount to $14 billion each year. Yet despite the high-volume sales of asthma drugs, in 73% of patients the disease is poorly controlled. For pharmaceutical firms and start-ups, the complex, multifactorial disease offers tantalizing possibilities; it's an enormous, yet underserved market with many points of entry, mechanistically speaking.
US Supply Chain In Brief: White House Aims To Deliver With Block Stowing And Industrial Base Expansion
Biden administration works to expedite medical supplies and expand medical countermeasures production, while US FDA's DSCSA anti-counterfeiting paperwork burden estimate surges.
Care Needed With Plain Language Summaries Of EU Study Results
The EU will make it mandatory for clinical trial sponsors to prepare layperson summaries of their study results. Industry practices around content presentation, translation and dissemination of these documents will be keenly watched.